Altered TNF-α and IFN-γ levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection

Infection, Genetics and Evolution

Volumn 11, Issue 7, 2011, Pages 1624-1630

  Zhang, Guoyu ^a   Li, Zhu ^a   Han, Qunying ^a   Li, Na ^a   Zhu, Qianqian ^a   Li, Fang ^a   Lv, Yi ^a   Chen, Jinghong ^b   Lou, Sai ^a   Liu, Zhengwen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chronic HBV infection; Interferon ; Polymorphism; Programmed cell death 1; Tumor necrosis factor

Indexed keywords

ALPHA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENOTYPE; HAPLOTYPE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; T LYMPHOCYTE ACTIVATION;

BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

HEPATITIS B VIRUS;

EID: 80053570509     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.06.004     Document Type: Article

References (58)

1. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8:765-772.
2. Akpolat N., Yahsi S., Godekmerdan A., Demirbag K., Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J. Gastroenterol. 2005, 11:3260-3263.
3. Basturk B., Karasu Z., Kilic M., Ulukaya S., Boyacioglu S., Oral B. Association of TNF-alpha -308 polymorphism with the outcome of hepatitis B virus infection in Turkey. Infect. Genet. Evol. 2008, 8:20-25.
4. Bayley J.P., de Rooij H., van den Elsen P.J., Huizinga T.W., Verweij C.L. Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-alpha promoter. Cytokine 2001, 14:316-323.
5. Bellamy R., Ruwende C., Corrah T., McAdam K.P., Thursz M., Whittle H.C., et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. Infect. Dis. 1999, 179:721-724.
6. Bennet A.M., Alarcón-Riquelme M., Wiman B., de Faire U., Prokunina-Olsson L. Decreased risk for myocardial infarction and lower tumor necrosis factor-alpha levels in carriers of variants of the PDCD1 gene. Hum. Immunol. 2006, 67:700-705.
7. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 2007, 81:4215-4225.
8. Cheong J.Y., Cho S.W., Hwang I.L., Yoon S.K., Lee J.H., Park C.S., et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. Gastroenterol. Hepatol. 2006, 21:1163-1169.
9. Chinese Society of Infectious Diseases and Parasitology and the Chinese Society of Hepatology Proposal of prevention and treatment of viral hepatitis. Zhonghua Nei Ke Za Zhi (Chin J Intern Med). 2001, 40:62-68.
10. Daniels H.M., Meager A., Eddleston A.L., Alexander G.J., Williams R. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 1990, 335:875-877.
11. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
12. Du T., Guo X.H., Zhu X.L., Li J.H., Lu L.P., Gao J.R., et al. Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. J. Viral Hepat. 2006, 13:618-624.
13. Duan S., Zhang G., Han Q., Li Z., Liu Z., Chen J., et al. CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with -318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients. Mol. Biol. Rep. 2010, 10.1007/s11033-010-0660-7.
14. Evans A., Riva A., Cooksley H., Phillips S., Puranik S., Nathwani A., et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008, 48:759-769.
15. Falasca K., Ucciferri C., Dalessandro M., Zingariello P., Mancino P., Petrarca C., et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 2006, 36:144-150.
16. Fisicaro P., Valdatta C., Massari M., Loggi E., Biasini E., Sacchelli L., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010, 138:682-693.
17. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
18. Gilles P.N., Guerrette D.L., Ulevitch R.J., Schreiber R.D., Chisari F.V. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 1992, 16:655-663.
19. González-Amaro R., García-Monzón C., García-Buey L., Moreno-Otero R., Alonso J.L., Yagüe E., et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J. Exp. Med. 1994, 179:841-848.
20. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
21. Höhler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Büschenefelde K.H., Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin. Exp. Immunol. 1998, 111:579-582.
22. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11:3887-3895.
23. Ishizaki Y., Yukaya N., Kusuhara K., Kira R., Torisu H., Ihara K., et al. PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis. Hum. Genet. 2010, 127:411-419.
24. Karimi M., Goldie L.C., Cruickshank M.N., Moses E.K., Abraham L.J. A critical assessment of the factors affecting reporter gene assays for promoter SNP function: a reassessment of -308 TNF polymorphism function using a novel integrated reporter system. Eur. J. Hum. Genet. 2009, 17:1454-1462.
25. Kim Y.J., Lee H.S., Yoon J.H., Kim C.Y., Park M.H., Kim L.H., et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum. Mol. Genet. 2003, 12:2541-2546.
26. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997, 34:391-399.
27. Lara-Pezzi E., Majano P.L., Gómez-Gonzalo M., García-Monzón C., Moreno-Otero R., Levrero M., et al. The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology 1998, 28:1013-1021.
28. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
29. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337:1733-1745.
30. Lettow I., Berres M.L., Schmitz P., Müller T., Berg T., Neumann U.P., et al. A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. Hum. Immunol. 2011, 72:273-277.
31. Li H.Q., Li Z., Liu Y., Li J.H., Dong J.Q., Gao J.R., et al. Association of -238G/A and -857C/T polymorphisms of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection. Biomed. Environ. Sci. 2006, 19:133-136.
32. Liu Q., Thorland E.C., Heit J.A., Sommer S.S. Overlapping PCR for bidirectional PCR amplification of specific alleles: a rapid one-tube method for simultaneously differentiating homozygotes and heterozygotes. Genome Res. 1997, 7:389-398.
33. Lu L.P., Li X.W., Liu Y., Sun G.C., Wang X.P., Zhu X.L., et al. Association of -238G/A polymorphism of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection in Chinese Han population. World J. Gastroenterol. 2004, 10:1810-1814.
34. Maier H., Isogawa M., Freeman G.J., Chisari F.V. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol. 2007, 178:2714-2720.
35. Mancini M., Hadchouel M., Tiollais P., Michel M.L. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. J. Immunol. 1998, 161:5564-5570.
36. Miyazoe S., Hamasaki K., Nakata K., Kajiya Y., Kitajima K., Nakao K., et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am. J. Gastroenterol. 2002, 97:2086-2092.
37. Niro G.A., Fontana R., Gioffreda D., Valvano M.R., Lacobellis A., Facciorusso D., et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int. 2005, 25:1175-1181.
38. Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 2001, 98:13866-13871.
39. Peng G., Li S., Wu W., Tan X., Chen Y., Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol. Immunol. 2008, 45:963-970.
40. Phillips S., Chokshi S., Riva A., Evans A., Williams R., Naoumov N.V. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 2010, 184:287-295.
41. Suri D., Schilling R., Lopes A.R., Mullerova I., Colucci G., Williams R., et al. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J. Hepatol. 2001, 35:790-797.
42. Thio C.L., Thomas D.L., Karacki P., Gao X., Marti D., Kaslow R.A., et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J. Virol. 2003, 77:12083-12087.
43. Thio C.L., Mosbruger T., Astemborski J., Greer S., Kirk G.D., O'Brien S.J., et al. Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J. Virol. 2005, 79:9192-9196.
44. Thio C.L., Astemborski J., Bashirova A., Mosbruger T., Greer S., Witt M.D., et al. Genetic protection against hepatitis B virus conferred by CCR5Delta32: evidence that CCR5 contributes to viral persistence. J. Virol. 2007, 81:441-445.
45. Thomas H.C., Foster G.R., Sumiya M., McIntosh D., Jack D.L., Turner M.W., et al. Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 1996, 348:1417-1419.
46. Thursz M.R., Kwiatkowski D., Allsopp C.E., Greenwood B.M., Thomas H.C., Hill A.V. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 1995, 332:1065-1069.
47. Toyonaga T., Hino O., Sugai S., Wakasugi S., Abe K., Shichiri M., et al. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc. Natl. Acad. Sci. USA 1994, 91:614-618.
48. Tseng S.Y., Otsuji M., Gorski K., Huang X., Slansky J.E., Pai S.I., et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 2001, 193:839-846.
49. Wang B., Wang J., Zheng Y., Zhou S., Zheng J., Wang F., et al. A study of TNF-alpha -238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology 2010, 42:674-680.
50. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 1997, 94:3195-3199.
51. Xie Z., Chen Y., Zhao S., Yang Z., Yao X., Guo S., et al. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol. Invest. 2009, 38:624-638.
52. Xu X.W., Lu M.H., Tan D.M. Association between tumour necrosis factor gene polymorphisms and the clinical types of patients with chronic hepatitis B virus infection. Clin. Microbiol. Infect. 2005, 11:52-56.
53. Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., et al. Immune effectors required for hepatitis B virus clearance. Proc. Natl. Acad. Sci. USA 2010, 107:798-802.
54. Yuen M.F., Lau C.S., Lau Y.L., Wong W.M., Cheng C.C., Lai C.L. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999, 29:1248-1251.
55. Zaykin D.V., Westfall P.H., Young S.S., Karnoub M.A., Wagner M.J., Ehm M.G. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum. Hered. 2002, 53:79-91.
56. Zhang Z., Zhang J.Y., Wherry E.J., Jin B., Xu B., Zou Z.S., et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 2008, 134:1938-1949.
57. Zhang G., Liu Z., Duan S., Han Q., Li Z., Lv Y., et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum. Immunol. 2010, 71:1209-1213.
58. Zheng M.H., Qiu L.X., Xin Y.N., Pan H.F., Shi K.Q., Chen Y.P. Tumor necrosis factor-alpha -308A allele may have a protective effect for chronic hepatitis B virus infection in Mongoloid populations. Int. J. Infect. Dis. 2010, 14:e580-e585.